Related Experiment Video
Updated: Aug 12, 2026
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Phase II trial of piperazinedione in metastatic sarcoma
Abstract:
Thirty-five patients with metastatic sarcomas received piperazinedione 9 mg/m2 every 3 weeks. Of 27 evaluable patients, 3 patients had stable disease for at least 6 weeks. The dose-limiting toxicity was myelosuppression. Piperazinedione is inactive in patients with drug-resistant metastatic sarcomas.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
10:27Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts
Published on: July 25, 2020